Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Abbott

Status and phase: Completed; Phase 4

Conditions: End Stage Renal Disease; Secondary Hyperparathyroidism

Treatments: Drug: paricalcitol injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT00053547

2001-022

Details and patient eligibility

About

The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

Sex: All

Ages: 2 to 20 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Subjects ages 2-20 with ESRD on hemodialysis with Secondary hyperparathyroidism

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind